

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
28 June 2001 (28.06.2001)

PCT

(10) International Publication Number  
WO 01/45760 A1

(51) International Patent Classification<sup>7</sup>: A61L 24/10, 26/00

(21) International Application Number: PCT/BE00/00152

(22) International Filing Date:  
20 December 2000 (20.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/469,302 22 December 1999 (22.12.1999) US  
PCT/BE00/94 16 August 2000 (16.08.2000) BE

(71) Applicants and  
(72) Inventors: PHILIPPART, Pierre [BE/BE]; Avenue Chanoine Roose 9, B-1070 Brussels (BE). BRASSEUR, Michèle [BE/BE]; Avenue des Frères Becqué 15, B-1082 Brussels (BE).

(74) Agents: POWIS DE TENBOSSCHE, Roland et al.; Cabinet Bede S.A., Place de l'Alma 3, B-1200 Brussels (BE).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/45760 A1

(54) Title: BONE GENERATING PRODUCT

(57) Abstract: The bone generating product comprises a coagulated matrix of platelet rich plasma with a recombinant compound for generating thrombin in presence of at least a phospholipid, and an effective amount of calcium containing compound dispersed in the matrix for inducing the formation of bone.

## BONE GENERATING PRODUCT

5

### ABSTRACT OF THE DISCLOSURE

The bone generating product comprises a coagulated matrix of platelet rich plasma with a recombinant compound for generating thrombin in presence of at least a 10 phospholipid, and an effective amount of calcium containing compound dispersed in the matrix for inducing the formation of bone.

### THE PRIOR ART

15 Many researches have been made for the preparation of bone substitute or implant.

For the preparation of bone substitute or implant, it is known to treat human bone by chemicals for destroying prions. The so treated human bone acts as a porous matrix suitable for the growth of cells after its implant.

20

It has also been proposed to prepare artificial matrix or sponge from collagen containing material and to use said matrix or sponge as bone substitute.

Example 4 of US 5,733,545 discloses the preparation of clot from a mixture 25 containing a plasma-buffy coat concentrate and ground dry bone or from a plasma-buffy coat concentrate and  $\text{CaCl}_2$ , said latter compound being used for ensuring the coagulation of the mixture. In said example 4, it is stated that the chelation of the plasma-buffy coat concentrate containing ground dry bone is possibly due to the presence of calcium from the solid bone. In said example, it is clearly stipulated that 30 the use of thrombin is a cause of patient complications.

However, the bone substitute obtained by mixing a plasma-buffy coat concentrate and ground dry bone was not suitable for the bone generation.

It has now been found a bone generating product, i.e. a product when implanted in a patient, allows a rapid cell colonization and the generation of bone. For obtaining a generation of bone, the bone generating product has to be prepared by using platelet rich plasma, a recombinant thrombin generating product, at least a phospholipid and an effective amount of calcium containing compound dispersed in the matrix for inducing the formation of bone. The recombinant tissue factor with or in presence of a phospholipid acts as a recombinant thrombin generating product, but also as a means for degranulocyte platelet and as a means for liberating growth factor present in the platelet. Preferably, at least a part of the calcium containing compound is made from bone particles. For example, at least 30%, preferably at least 50% by weight of the calcium containing compound is made from bone particles, preferably of not denatured bone particles. The presence of the bone particles in the bone generating product of the invention is considered as improving the generation of bone, as said bone particles contain bone morphogenic proteins as well growth factors for directing the tissue factor to produce bone. It is assumed that the excellent bone generation obtained by implanting the bone generating product of the invention to patient is due to the presence of the various factors (growth factors, etc.) present in the platelet rich plasma and of calcium containing compound(s) (preferably bone particles). The presence of recombinant tissue factor is also preferred. It is assumed that the recombinant tissue factor induces a protein containing matrix, factor suitable for inducing and accelerating the formation of bone in presence of calcium containing compound. When using substantially only platelet rich plasma, bone particles and a recombinant thrombin generating compound, it is assumed that the different factors present in the product of the invention act substantially as in the body (the ratio of one factor with respect to another being substantially equal to the said ratio in the body), whereby improving the generation of bone.

BRIEF DESCRIPTION OF THE INVENTION

The bone generating product of the invention comprises a coagulated matrix of platelet rich plasma with a recombinant compound for generating thrombin, said

5 matrix comprising at least a phospholipid and an effective amount of calcium containing compound for generating bone dispersed in the matrix. Preferably, the calcium containing compound is bone particles, possibly mixed with other calcium containing compound. Preferably, at least 30% by weight, advantageously at least 50% by weight of the calcium containing compound consists of bone particles.

10 Examples of calcium containing compounds are :  $\text{CaCl}_2$ ,  $\beta$ -tricalcium phosphate, bone particles (denatured bone), bone particles (not denatured bone), apatite, aspidine, calcium sulfate, calcium carbonate, hydroxy apatite, hydroxy apatite (from coral reef), calcium gluconolactate, calcium gluconate, calcium lactate, calcium glutoniate and mixtures thereof.

15

Advantageously, the recombinant compound for generating thrombin is a recombinant thromboplastine.

Preferably, the bone generating product of the invention comprises two or more than two different phospholipids.

20

According to an advantageous embodiment, the recombinant compound for generating thrombin is combined with one, preferably at least two different phospholipids.

25

According to an preferred embodiment, the recombinant compound for generating thrombin is combined with at least a phospholipid selected from the group consisting of phosphatidylserine, derivatives thereof, phosphatidylserine having at least one fatty acid side chain, phosphatidylcholine, derivatives thereof, phosphatidylcholine having at least one fatty acid side chain, and mixtures thereof.

30

Preferably, the recombinant compound for generating thrombin is combined with at least a phospholipid selected from the group consisting of phosphatidylserine, derivatives thereof, phosphatidylserine having at least one fatty acid side chain,

phosphatidylcholine, derivatives thereof, phosphatidylcholine having at least one fatty acid side chain, and mixtures thereof, the fatty acid side chain being selected from the group consisting of fatty acid chains with at least one double bond and with 6 to 24 carbon atoms, most preferably with 16 to 18 carbon atoms.

5

According to a most preferred embodiment, the recombinant compound for generating thrombin is combined with a mixture of at least two phospholipids, a first phospholipid being selected from the group consisting of phosphatidylserine, derivatives thereof, phosphatidylserine having at least one fatty acid side chain, and mixtures therof, the fatty acid side chain of the phosphatidylserine having at least one fatty acid side chain being selected from the group consisting of fatty acid chains with at least one double bond and with 6 to 24 carbon atoms, preferably 16 to 18, while the second phospholipid is selected from the group consisting of phosphatidylcholine, derivatives thereof, phosphatidylcholine having at least one fatty acid side chain, and mixtures thereof, the fatty acid side chain of the phosphatidylcholine having at least one fatty acid side chain being selected from the group consisting of fatty acid chains with at least one double bond and with 6 to 24 carbon atoms.

10 20 In the bone generating product of the invention, the bone particles are preferably bone particles selected from the group consisting of craniofacial bone particles, iliac bone particles and mixture thereof. Preferably, the bone particles are particles of not denatured bones. Advantageously, the bone particles have an average particle size comprised between 0.5 mm and 5mm, preferably comprised between 0.5 and 3mm, most preferably about 1 mm (average in weight). The bone particles have for example the form of chips or flakes having an average particle size comprised between 0.5 mm and 5mm, preferably comprised between 0.5 and 3mm, most preferably about 1 mm (average in weight). According to a possible embodiment, the bone particles consist of a mixture of denatured bone particles (for example bone particles prepared by grinding a bone that has been treated by chemical(s), by irradiation, etc. for rendering it prion free.) and of not denatured bone particles. When using some denatured bone particles, the said particles of denatured bone can

15 25 30

have a particle size lower than 0.5mm, as said denatured bone particles are used for adding some calcium to the product.

The bone generating product of the invention comprises for example from 5% to 5 50% by volume of bone particles, advantageously from 10 to 40%, preferably from 20 to 30% by volume of bone particles. The bone particles forms preferably more than 90% by weight of the calcium containing compound present in the bone generating product of the invention.

10 According to an advantageous embodiment of the bone generating product of the invention, the coagulated matrix is a coagulated matrix of platelet rich plasma having a platelet concentration of 1,500,000 to 2,000,000 platelets per microlitre of the matrix forming agents, and preferably 0.05 to 0.4 µg thromboplastine in dry form per microlitre of the matrix forming agents. The platelet concentration is a 15 concentration adapted for ensuring the viability of the platelets at 37°C.

In order to avoid as much as possible complication and in order to improve as much as possible the graft of the bone generated on the natural bone of a patient, the platelet rich plasma used is prepared from the plasma of the patient and/or from a 20 plasma histocompatible with the patient (i.e. immunologic histocompatibility), while the bone particles are prepared from a bone of the patient and/or from bone(s) histocompatible with the patient (i.e. immuno histocompatibility).

The bone generating product of the invention can possibly contain further 25 components or additives, such as growth factor (superfamily BTGF and family of BMP, such as BMP-1, etc.), gene coding BMP and/or BTGF, steric factors, calcium containing compounds, drugs, fatty acids, antibiotics or mixtures of antibiotics (preferably compound(s) having an anti osteoclasts effect, such as antibiotics of the tetracyclin group, Vibramycin ®, Doxycycline ®, minocycline, minocin ® (Wyeth-Lederlee), and mixtures of compound(s) having an anti osteoclasts effect with another antibiotic(s), such as macrolide, penicillin based compounds, etc.), bactericide, virucide, fibrinogene, compounds inducing the formation of a matrix,

buffer, zwitterionic buffer system at physiological pH, etc. and mixtures of said compounds or additives.

According to a detail of a preferred embodiment, the bone generating product

5   contains from 0.001 to 10% by weight antibiotic or antibiotics (calculated in its dry form), advantageously from 0.01% to 5% by weight, preferably from 0.02 to 1%, for example from 0.05 to 0.4% by weight. The antibiotic is advantageously selected from the group consisting of antibiotics having an anti osteoclasts effect (more specifically antibiotics of the tetracyclin group, Vibramycin®, Doxycycline®, minocycline, minocin® (Wyeth-Lederle)), mixtures of antibiotics having an anti osteoclasts effect, and mixtures of one or more antibiotics having an anti osteoclasts effect with one or more other antibiotic(s) (preferably macrolide, penicillin based compounds, etc. and mixtures thereof).

10   

15   Before its gelling, the bone generating product has advantageously a pH substantially equal to the physiological pH, for example a pH comprised between 6.5 and 8, preferably about 7-7.5, pH measured at 37°C.

The invention relates also to a method for the preparation of a bone generating

20   product comprising a coagulated matrix of platelet rich plasma with a recombinant compound for generating thrombin, and bone particles dispersed in the said matrix, in which

- a substantially homogeneous mixture is formed by mixing of platelet rich plasma with an effective amount of calcium containing compound(s) for inducing the

25   bone generation when adding to the mixture a recombinant thrombin generating compound and a phospholipid,

- a recombinant thrombin generating compound and at least one phospholipid are added and mixed to the mixture of bone particles and platelet rich plasma, and
- the mixture recombinant thrombin generating compound, platelet rich plasma, phospholipid and bone particles is kept under conditions for ensuring a

30   coagulation of the platelet rich plasma and the formation of a bone generating matrix.

Preferably, the coagulation is carried out in presence of oxygen and substantially without stirring. The said coagulation is most preferably carried out at a temperature comprised between 35°C and 40°C, more specifically at a temperature of about 5 37°C.

In the process of the invention, the recombinant compound for generating thrombin used for the coagulation is advantageously a recombinant thromboplastine.

10 Advantageously, at least two different phospholipids are added to the mixture selected from the group consisting of mixture of recombinant thrombin generating compound, platelet rich plasma and bone particles, and mixture of platelet rich plasma and bone particles, said addition being preferably carried out when adding the recombinant thrombin generating compound.

15 In the process of the invention, the recombinant thrombin generating compound is advantageously combined with phospholipid, preferably with phospholipids, the said compound combined with phospholipid(s) having advantageously the form of a lyophilized product, such as a lyophilized cake, powder or granules.

20 According to a preferred method of the invention, the recombinant compound for generating thrombin is combined with at least a phospholipid selected from the group consisting of phosphatidylserine, derivatives thereof, phosphatidylserine having at least one fatty acid side chain, phosphatidylcholine, derivatives thereof, 25 phosphatidylcholine having at least one fatty acid side chain, and mixtures thereof, the fatty acid side chain being advantageously selected from the group consisting of fatty acid chains with at least one double bond and with 6 to 24 carbon atoms, preferably with 16-18 carbon atoms.

According to a most preferred embodiment of the process, the recombinant 30 compound for generating thrombin is combined with a mixture of at least two phospholipids, a first phospholipid being selected from the group consisting of phosphatidylserine, derivatives thereof, phosphatidylserine having at least one fatty

acid side chain, and mixtures thereof, the fatty acid side chain of the phosphatidylserine having at least one fatty acid side chain being selected from the group consisting of fatty acid chains with at least one double bond and with 6 to 24 carbon atoms while the second phospholipid is selected from the group consisting of

5 phosphatidylcholine, derivatives thereof, phosphatidylcholine having at least one fatty acid side chain, and mixtures thereof, the fatty acid side chain of the phosphatidylcholine having at least one fatty acid side chain being selected from the group consisting of fatty acid chains with at least one double bond and with 6 to 24 carbon atoms.

10 Preferably, at least a part of the calcium containing compound(s) is formed by bone particles, advantageously bone particles selected from the group consisting of craniofacial bone particles, iliac bone particles and mixture thereof. The bone particles are advantageously particles of not denatured bones. Said bone particles

15 can possibly consist of a mixture of not denatured bone particles and denatured bone particles. The bone particles have advantageously an average (by weight) particle size comprised between 0.5 mm and 5mm, preferably comprised between 0.5 and 3mm, most preferably of about 1 mm.

20 In the method of the invention, the amount of bone particles added to the platelet rich plasma corresponds for example to about 5% to 50% by volume, advantageously from 10 to 40%, preferably from 20% to 30% by volume of the mixture platelet rich plasma and bone particles.

25 Advantageously, the platelet rich plasma used in the method of the invention has a platelet concentration of 1,500,000 to 2,000,000 platelets per microlitre of the matrix forming agents.

30 Preferably, the mixture platelet rich plasma, bone particles and recombinant thrombin generating compound has a platelet concentration of 1,500,000 to 2,000,000 platelets per microlitre of the mixture without bone particles and contains 0.05 to 0.4 µg thromboplastine in dry form per microlitre of the mixture without bone particles.

According to a preferred method of the invention suitable for the preparation of a bone generating product for a patient, the platelet rich plasma is prepared from the plasma of the patient and/or from a plasma hystocompatible with the patient and in 5 which the bone particles are prepared from a bone of the patient and/or from a bone hystocompatible with the patient.

According to a detail of a preferred method of the invention, the coagulation of the platelet rich plasma is carried out in presence of at least one antibiotic and/or at least 10 one antibiotic is added to the mixture after the coagulation of the platelet rich plasma. The antibiotic or mixture of antibiotics can possibly be added to the bone particles and/or to the bone before its grinding and/or to the recombinant compound that generates thrombin and/or to a phospholipid. Preferably, an antibiotic or a mixture of antibiotics is mixed with the recombinant compound for generating 15 thrombin (recombinant compound that generates thrombin), preferably with a recombinant thromboplastine.

According to a detail of a preferred embodiment, the amount of antibiotic or 20 antibiotics added to the bone generating product or used during the coagulation of the platelet rich plasma bone generating product contains from 0.001 to 10% by weight antibiotic or antibiotics (calculated in its dry forms), advantageously from 0.01% to 5% by weight, preferably from 0.02 to 1%, for example from 0.05% to 0.4% by weight, more specifically from 0.2 to 0.3%. The antibiotic is 25 advantageously selected from the group consisting of antibiotics having an anti osteoclasts effect (more specifically antibiotics of the tetracyclin group, Vibramycin ®, Doxycycline ®, minocycline, minocin ® (Wyeth-Lederle)), mixtures of antibiotics having an anti osteoclasts effect, and mixtures of one or more antibiotics having an anti osteoclasts effect with one or more other antibiotic(s) (preferably 30 macrolide, penicillin based compounds, etc. and mixtures thereof).

Most preferably, at least one antibiotic is added to the mixture containing at least platelet rich plasma and calcium containing compound, before adding the recombinant compound that generates thrombin, but advantageously when adding the recombinant compound that generates thrombin.

5

The invention relates also to the use of a recombinant compound for generating thrombin in mixture with at least one phospholipid for the preparation of a bone generating product from a mixture of a platelet rich plasma and an effective amount of calcium containing compound for inducing bone generation.

10

A further object of the invention is a mixture containing a recombinant compound for generating thrombin, at least one phospholipid, and a calcium containing compound, the weight ratio calcium from the calcium containing compound / recombinant compound for generating thrombin being greater than 0.5, advantageously greater than 2.

15

The said has advantageously the form of a dry powder.

The calcium containing compound is preferably selected from the group consisting of calcium containing salts,  $\beta$ - tricalcium phosphate, particles of denatured bone and mixtures thereof.

20

Still a further object of the invention is a mixture containing a recombinant compound for generating thrombin, at least one phospholipid and at least one antibiotic. The weight ratio antibiotic(s) (as dry matter) present in the mixture/ recombinant compound for generating thrombin (as dry matter) present in the mixture is advantageously greater than 1:1, preferably greater than 3:1, most preferably greater than 5:1 and more specifically greater than 10:1. For example the said ratio is comprised between 5:1 and 50:1, more specifically between 10:1 and 25:1.

25

The antibiotic is advantageously selected from the group consisting of antibiotics having an anti osteoclasts effect (more specifically antibiotics of the tetracyclin group, Vibramycin  $\circledR$ , Doxycycline  $\circledR$ , minocycline, minocin  $\circledR$  (Wyeth-Lederle)),

mixtures of antibiotics having an anti osteoclasts effect, and mixtures of one or more antibiotics having an anti osteoclasts effect with one or more other antibiotic(s) (preferably macrolide, penicillin based compounds, etc. and mixtures thereof).

5 The recombinant compound that generates thrombin is advantageously a recombinant thromboplastine.

The invention relates also to a method for the preparation of a sealant, in which a fibrinogen containing solution is contacted, preferably mixed, with a recombinant 10 compound for generating thrombin in presence of at least a phospholipid. Advantageously, the recombinant compound for generating thrombin is a recombinant thromboplastine.

Advantageously, a gel is formed by contacting the fibrinogen containing solution 15 with a recombinant compound for generating thrombin in presence of at least a phospholipid, at least an antibiotic and at least an effective amount of a buffer, so that the gel is formed at a pH kept between 6 and 8, advantageously between 7 and 7.5.

20 Preferably, a buffered solution containing the antibiotic(s) and the buffer agent(s) is prepared and contacted with the fibrinogen containing solution. The pH of said buffered solution is advantageously comprised between 6 and 8, most preferably between 7 and 7.5. The buffered solution may possibly, but advantageously, contain 25 one or more recombinant compound for generating thrombin and/or one or more phospholipids.

Possible buffers are for example TRIS buffer, solution of Ringé, sodium bicarbonate, and mixture thereof.

30 Preferably, the fibrinogen containing solution is contacted with a recombinant compound for generating thrombin in presence of at least two different phospholipids.

Most preferably, the fibrinogen containing solution is contacted with a recombinant compound for generating thrombin in presence of at least one phospholipid selected from the group consisting of phosphatidylserine, derivatives thereof,

5 phosphatidylserine having at least one fatty acid side chain, phosphatidylcholine, derivatives thereof, and phosphatidylcholine having at least one fatty acid side chain, preferably at least two phospholipids selected from said group.

The fatty acid side chain of phosphatidylcholine is advantageously selected from the group consisting of fatty acid chains with at least one double bond and with 6 to 10 24 carbon atoms, preferably with 16 to 18 carbon atoms.

Before the formation of the sealant, the mixed solutions have advantageously a pH substantially equal to the physiological pH, for example a pH comprised between 6.5 and 8, preferably about 7-7.5, pH measured at 37°C.

15

Advantageously, a platelet rich plasma is used as fibrinogen containing solution.

The platelet rich plasma has advantageously a platelet concentration of 1,500,000 to 2,000,000 platelets per microlitre.

20 Preferably, the platelet rich plasma having a platelet concentration of 1,500,000 to 2,000,000 platelets per microlitre, while from 0.05 to 0.4 µg thromboplastine in dry form per microlitre and from 0.01 to 4 µg (advantageously from 0.1 to 0.4 µg, preferably from 0.2 to 0.3 µg) antibiotic(s) (as dry matter) per microlitre are contacted with the platelet rich plasma in presence of an effective amount of buffer agent(s) for regulating the pH between 6 and 8, advantageously between 7 and 7.5 25 during the gelling.

When using a platelet rich plasma, in order to avoid as much as possible complication and in order to improve as much as possible the graft of the sealant in a patient, the platelet rich plasma used is prepared from the plasma of the patient 30 and/or from a plasma hystocompatible with the patient (i.e. immunologic hystocompatibility).

The fibrinogen containing solution, preferably the platelet rich plasma, is advantageously contacted with at least a recombinant compound for generating thrombin in presence of at least one, preferably two different phospholipids, and in presence of at least an antibiotic.

5

Preferably, the fibrinogen containing solution, preferably the platelet rich plasma, is contacted with a solution containing at least a recombinant compound for generating thrombin and at least one, preferably two different phospholipids.

- 10 When using one or more antibiotics, the amount of antibiotic(s) used is advantageously such that the sealant contains from 0.001 to 10% by weight antibiotic or antibiotics, advantageously from 0.01% to 5% by weight, preferably from 0.02 to 1%, most preferably from 0.05 to 0.4%. The weight ratio antibiotic(s) (calculated as dry matter) present in the sealant mixture / recombinant compound for
- 15 generating thrombin used in the sealant mixture is advantageously greater than 1:1, preferably greater than 3:1, most preferably greater than 5:1 and more specifically greater than 10:1. For example the said ratio is comprised between 5:1 and 50:1, more specifically between 10:1 and 25:1.
- 20 The antibiotic is advantageously selected from the group consisting of antibiotics having an anti osteoclasts effect (more specifically antibiotics of the tetracyclin group, Vibramycin ®, Doxycycline ®, minocycline, minocin ® (Wyeth-Lederle)), mixtures of antibiotics having an anti osteoclasts effect, and mixtures of one or more antibiotics having an anti osteoclasts effect with one or more other antibiotic(s)
- 25 (preferably macrolide, penicillin based compounds, etc. and mixtures thereof).

The invention relates also a kit for the preparation of a sealant according to the invention, said kit comprising:

- 30 - a first vial containing a fibrinogen containing material, preferably a fibrinogen containing solution;

- a second vial containing a recombinant compound for generating thrombin, preferably a solution containing said recombinant compound;
- possibly, a third vial containing a solution to be added to the first vial and/or second vial for the preparation of a fibrinogen containing solution and/or a solution containing a recombinant compound for generating thrombin;

5 in which the first vial and/or the second vial and/or the third vial contains at least a phospholipid, preferably at least two different phospholipids, and in which the first vial and/or the second vial and/or the third vial (preferably the second and/or the third vial) contains at least an antibiotic.

10

Advantageously, the first vial and/or the second vial and/or the third vial contains at least a buffer agent. Preferably, the second vial contains at least a phospholipid and at least an antibiotic, while the third vial contain the buffer agent(s).

15

Most preferably, the first vial contains fibrinogen containing material in a dry form, while the second vial contains a recombinant compound for generating thrombin in a dry form.

Details and characteristics of the product and the process of the invention will appear from the following description of examples.

20

#### DESCRIPTION OF EXAMPLES

For the preparation of the said examples, the following products have been used:

25 PRP : platelet rich plasma of the patient to which a bone graft has to be placed. The platelet concentration of the plasma was 1,800,000 platelets per microliter of the plasma. The PRP was subjected to known usual treatments for the removal leucocyte, for obtaining a maximum proportion of life platelets, for bacteriological control, said PRP being active at least for 5 days. Prior its use, the PRP was shaken

30 at a temperature of 37°C, the said shaking being achieved by shaking the container containing the PRP.

Thromboplastine : The thromboplastine used was a thromboplastine sold under the Trademark INNOVIN by the company DADE AG( Düdingen, Switzerland ). The thromboplastine is a recombinant human tissue factor lyophilized combined with synthetic phospholipids, namely phosphatidylserine and phosphatidylcholine, said phospholipids having at least one fatty acid side chain, the fatty acid side chain being selected from the group consisting of fatty acid chains with at least one double bond and with 16-18 carbon atoms. Innovin is free of prothrombin, free of factor FVII, and free of factor FX. Calcium is present in Innovin. Innovin is a known product for test purposes. Innovin contains also some calcium, a zwitterionic buffer system at physiological pH.

Bone particles : The bone particles have been prepared from iliac bones or craniofacial bone of the patient to whom a bone graft is needed. The fresh bone of the patient was ground in bone flakes (bone meal) having an average diameter of 1mm. The bone particles are added to the PRP just after their preparation.

Water : water used is distilled, sterilized, pyrogen free water.

#### Example 1

In said example, 50ml of PRP was placed in a sterilized container. A volume of 10ml of bone particles (craniofacial provenance) was added to the PRP and mixed. The recipient is then heated under sterile conditions at 37.5°C (for example by using a water bath having a temperature of 37.5°C, the said bath containing water and 0.9% NaCl), in an oxygen containing atmosphere.

10 mg Innovin was mixed with 2 ml distilled, sterile and pyrogen free water. The mixture water + Innovin was added to the PRP + bone particles mixture kept at a temperature of 37.5°C.

After about 10minutes, without stirring, a gel is formed in the recipient, said gel being a bone generating product suitable for implant to the patient.

Example 2

Example 1 has been repeated, except that 20mg Innovin was mixed with 2 ml  
5 distilled, sterile and pyrogen free water, and was added to the mixture PRP + bone  
particles.

Examples 3 to 9

10 In said examples, example 1 was repeated except that the amount of reagents used  
was different.

| Example                                | 3  | 4  | 5  | 6  | 7  | 8  | 9  |
|--|----|----|----|----|----|----|----|
| PRP(ml)                                | 50 | 50 | 50 | 50 | 50 | 50 | 50 |
| Bone particles<br>(ml)<br>craniofacial | 10 | 10 | 15 | 40 | 30 | 25 | 50 |
| Innovin (mg)                           | 20 | 10 | 10 | 10 | 10 | 20 | 10 |
| Water (ml)                             | 2  | 2  | 2  | 2  | 2  | 4  | 4  |

Examples 10 to 19

5 In said examples, example 1 was repeated except that the amount of reagents used was different.

| Example                                | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 |
|--|----|----|----|----|----|----|----|----|----|----|
| PRP(ml)                                | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 |
| Bone particles<br>(ml)<br>craniofacial |    |    |    | 10 | 20 | 10 | 10 | 10 | 20 | 10 |
| Bone particles<br>(ml) iliac           | 10 | 20 | 40 | 10 | 10 | 20 | 10 | 10 | 20 | 30 |
| Innovin(mg)                            | 20 | 20 | 10 | 20 | 10 | 10 | 20 | 30 | 10 | 10 |
| Water (ml)                             | 2  | 2  | 4  | 2  | 2  | 2  | 2  | 2  | 4  | 4  |

10 The bone generating product of said examples 1 to 19 having the form of a gel can easily be implanted in a patient, for example in a human patient suffering a major maxillofacial atrophy. The bone generating product of the invention can easily be compacted in recesses of bones, and can be easily be shaped.

15 The bone generating product of the invention was used for volunteers suffering a major maxillofacial atrophy. Sinus lift grafts and on lay graft on the maxillofacial bone have been carried out. These tests have shown a bone growth or the generation of bone where the bone generating product of the invention was applied.

Example 20

20 A human bone was denatured and  $\gamma$ -irradiated so as to be prion free. The bone was ground in particles having an average (by weight) of 0.2mm. After drying, 10g of bone particles were dry mixed with 10 mg dry INNOVIN, so as to obtain a mixture

of recombinant compound for generating thrombin, phospholipid and a high level of calcium containing compound.

5 The so prepared mixture was then used for the preparation of a bone generating product of the invention.

The method of example 1 was repeated, except that the mixture 10 mg INNOVIN + 10g denatured bone particles was used instead of 10mg INNOVIN alone, and except that a larger amount of sterile water was used (5-10 ml), amount water adjusted so as 10 to prepare a pasta.

#### Example 21

Example 1 was repeated, except that before adding the recombinant 15. thromboplastine, 200 $\mu$ g Vibramycin ® per ml mixture of PRP and bone particles was added.

Example 22

Example 1 was repeated, except that before adding the recombinant  
5 thromboplastine, 100 $\mu$ g Minocycline (Minocin ®) per ml mixture of PRP and bone  
particles was added.

Example 23

10 Example 1 was repeated, except that before adding the recombinant  
thromboplastine, 50 $\mu$ g Minocycline (Minocin ®) per ml mixture of PRP and bone  
particles was added.

Example 24

15 Example 1 was repeated, except that before adding the recombinant  
thromboplastine, 20 $\mu$ g Minocycline (Minocin ®) per ml mixture of PRP and bone  
particles was added.

20 Example 25

10mg of Innovin was mixed with 100mg Vibramycin ®. The presence of  
Vibramycin seems to improve the stability and efficiency of the Innovin.

25 The mixture Innovin – vibramycin ® was used as in example 1 for the preparation of  
the gel.

Example 26

30 10 mg Innovin was mixed with 5 ml water. Thereafter, 100mg Vibramycin was  
added to the said aqueous mixture of Innovin. The mixture was then lyophilized so  
as to obtain a powder or cake containing Innovin and Vibramycin.

The lyophilized product was then used as in example 25.

As in the preparation process of Innovin, an aqueous mixture of recombinant  
5 thromboplastine and phospholipid is lyophilized, it is possible to add the said  
antibiotic (for example Vibramycin ) to the aqueous mixture before its lyophilization  
(for example before and/or after the addition of  $\text{Ca}^{++}$ , buffer and stabilizers to the  
mixture as carried out in the preparation process of Innovin).

10 Examples 27 to 29

Examples 24 to 26 were repeated except that Minocin ® (Wyeth-Lederle) was used  
instead of Vibramycin ®.

15 Examples 30 to 59

Examples 1 to 29 have been repeated except that the recombinant tissue factor  
4500L/B of American diagnostica Inc. was used instead of Innovin. The  
recombinant tissue factor 4500L/B2 of American diagnostica Inc. can also be used.

20

Example 60

A sealant was prepared by mixing 50 ml of PRP with 2ml aqueous solution  
containing 10mg Innovin, 100mg Minocin ® and a physiologically acceptable buffer  
25 (in an amount sufficient for having a pH of about 7.2 for the aqueous solution before  
its mixing with the PRP, for example a solution of sodium bicarbonate). A sealant  
gel was so obtained.

Example 61

30

50 ml PRP was placed in a chamber of a first syringe, while 2ml aqueous solution  
containing 10mg Innovin, 100mg Minocin ® and a physiologically acceptable buffer

(sodium bicarbonate) was placed in a chamber of a second syringe. The two syringes were connected to a mixer for mixing PRP with Innovin, Minocin and buffer before applying the mixture to the wound, and to a means for delivering to the mixer on a continuous manner 0.04ml Innovin solution per ml of PRP.

5

Example 62

Example 61 was repeated except that 10ml of an aqueous solution containing 10mg Innovin and 200 mg Vibramycin ® and buffer agent (the pH of the solution being 10 about 7.2) was used, and that the means delivers to the mixer on a continuous manner 0.2ml Innovin-Vibramycin solution per ml of PRP.

Example 63

15 A kit for the preparation of a sealant, said kit comprising:

- a first vial containing PRP ;
- a second vial containing Innovin and Vibramycin in a dry form,
- a third vial containing sterile water and a buffer (amount sufficient for ensuring a pH of 7.2, when mixing the three vials together, preferably the second and third vials are first mixed together and the mixture thereof is mixed with the content of the first vial) for reconstituting the solution containing Innovin-Vibramycin.

20 Advantageously, the kit further comprises means for mixing the PRP with the reconstituted Innovin-Vibramycin solution and means for applying the mixture on the wound, for example by spraying.

25

Example 64

30 Sealant composition of the invention and pasta (bone generating product), especially as prepared in the previous example, were used for coating an artificial bone, for example a bone having been submitted to one or more sterilization treatments.

WHAT WE CLAIM IS :

- 5 1. A method for the preparation of a sealant, in which a fibrinogen containing solution is contacted with a recombinant compound for generating thrombin in presence of at least a phospholipid, at least a buffer and at least an antibiotic.
- 10 2. The method of claim 1, in which a gel is formed by contacting the fibrinogen containing solution with a recombinant compound for generating thrombin in presence of at least a phospholipid, at least an antibiotic and at least a effective amount of buffer, so that the pH of the contacted fibrinogen solution is kept between 6 and 8, advantageously between 7 and 7.5 during the formation of the gel.
- 15 3. The method of claim 2, in which a buffered solution containing the antibiotic(s) and buffer agent(s) and possibly a recombinant compound for generating thrombin and possibly a phospholipid is prepared, said buffered solution having a pH comprised between 6 and 8, preferably between 7 and 7.5, and in which the fibrinogen containing solution is contacted with said buffered solution.
- 20 4. The method of anyone of the claims 1 to 3, in which the recombinant compound for generating thrombin is a recombinant thromboplastin.
- 25 5. The method of anyone of the claims 1 to 4, in which the fibrinogen containing solution is contacted with a recombinant compound for generating thrombin in presence of at least two different phospholipids.
- 30 6. The method of anyone of the claims 1 to 5, in which the fibrinogen containing solution is contacted with a recombinant compound for generating thrombin in presence of at least one phospholipid selected from the group consisting of phosphatidylserine, derivatives thereof, phosphatidylserine having at least one fatty acid side chain, phosphatidylcholine, derivatives thereof, and phosphatidylcholine

having at least one fatty acid side chain, preferably at least two phospholipids selected from said group.

7. The method of claim 6, in which the fatty acid side chain of phosphatidylcholine is selected from the group consisting of fatty acid chains with at least one double bond and with 6 to 24 carbon atoms, preferably with 16 to 18 carbon atoms.
8. The method of anyone of the claims 1 to 7, in which a platelet rich plasma is contacted with a recombinant compound for generating thrombin in presence of at least a phospholipid and a buffer agent.
9. The method of claim 8, in which the platelet rich plasma has a platelet concentration of 1,500,000 to 2,000,000 platelets per microlitre.
10. The method of claim 8 or 9, in which the platelet rich plasma having a platelet concentration of 1,500,000 to 2,000,000 platelets per microlitre, while from 0.05 to 0.4 µg thromboplastine in dry form per microlitre and from 0.05 to 4 µg antibiotic(s) per microlitre are contacted with the platelet rich plasma in presence of an effective amount of buffer agent(s) for regulating the pH between 6 and 8, advantageously between 7 and 7.5 during the gelling.
11. A kit for the preparation of a sealant according to anyone of the claims 1 to 10, said kit comprising:
  - a first vial containing a fibrinogen containing material, preferably a fibrinogen containing solution;
  - a second vial containing a recombinant compound for generating thrombin, preferably a solution containing said recombinant compound;
  - possibly, a third vial containing a solution to be added to the first vial and/or second vial for the preparation of a fibrinogen containing solution and/or a solution containing a recombinant compound for generating thrombin;in which the first vial and/or the second vial and/or the third vial contains at least a phospholipid, preferably at least two different phospholipids, and in which the first

vial and/or the second vial and/or the third vial, preferably the second vial or the third vial, contains at least an antibiotic.

12. The kit of claim 11, in which the first vial and/or the second vial and/or the third  
5 vial contains at least a buffer agent.

13. The kit of claim 12, in which the second vial contains at least a phospholipid, at  
least a buffer agent and at least an antibiotic.

10 14. The kit of claim 11, in which the first vial contains fibrinogen containing  
material in a dry form, while the second vial contains a recombinant compound for  
generating thrombin in a dry form.

15 15. Bone generating product comprising a coagulated matrix of platelet rich plasma  
with a recombinant compound for generating thrombin in presence of at least a  
phospholipid, and an effective amount of calcium containing compound dispersed in  
the said matrix for inducing the formation of bone.

16. The bone generating product of claim 15, in which the calcium containing  
20 compound is selected from the group consisting of bone particles, mixture of bone  
particles with calcium containing additives.

17. The bone generating product of claim 15, in which the recombinant compound  
for generating thrombin is a recombinant thromboplastine.

25 18. The bone generating product of claim 15, which further comprises at least two  
different phospholipids.

19. The bone generating product of claim 15, in which the recombinant compound  
30 for generating thrombin is combined with phospholipids.

20. The bone generating product of claim 15, in which the recombinant compound for generating thrombin is combined with at least a phospholipid selected from the group consisting of phosphatidylserine, derivatives thereof, phosphatidylserine having at least one fatty acid side chain, phosphatidylcholine, derivatives thereof, 5 phosphatidylcholine having at least one fatty acid side chain, and mixtures thereof.

21. The bone generating product of claim 15, in which the recombinant compound for generating thrombin is combined with at least a phospholipid selected from the group consisting of phosphatidylserine, derivatives thereof, phosphatidylserine having at least one fatty acid side chain, phosphatidylcholine, derivatives thereof, phosphatidylcholine having at least one fatty acid side chain, and mixtures thereof, the fatty acid side chain being selected from the group consisting of fatty acid chains with at least one double bond and with 6 to 24 carbon atoms. 10

15 22. The bone generating product of claim 15, in which the recombinant compound for generating thrombin is combined with at least a phospholipid selected from the group consisting of phosphatidylserine, derivatives thereof, phosphatidylserine having at least one fatty acid side chain, phosphatidylcholine, derivatives thereof, phosphatidylcholine having at least one fatty acid side chain, and mixtures thereof, 20 the fatty acid side chain being selected from the group consisting of fatty acid chains with at least one double bond and with 16 to 18 carbon atoms.

23. The bone generating product of claim 15, in which the recombinant compound for generating thrombin is combined with a mixture of at least two phospholipids, a 25 first phospholipid being selected from the group consisting of phosphatidylserine, derivatives thereof, phosphatidylserine having at least one fatty acid side chain, and mixtures thereof, the fatty acid side chain of the phosphatidylserine having at least one fatty acid side chain being selected from the group consisting of fatty acid chains with at least one double bond and with 6 to 24 carbon atoms while the second 30 phospholipid is selected from the group consisting of phosphatidylcholine, derivatives thereof, phosphatidylcholine having at least one fatty acid side chain, and mixtures thereof, the fatty acid side chain of the phosphatidylcholine having at least one fatty acid side chain.

one fatty acid side chain being selected from the group consisting of fatty acid chains with at least one double bond and with 6 to 24 carbon atoms.

24. The bone generating product of claim 15, in which the calcium containing compound is selected from the group consisting of bone particles, mixture of bone particles with calcium containing additives, and in which the bone particles are bone particles selected from the group consisting of craniofacial bone particles, iliac bone particles and mixtures thereof.
- 10 25. The bone generating product of claim 15, in which the calcium containing compound is selected from the group consisting of bone particles, mixture of bone particles with calcium containing additives, and in which the bone particles are particles of not denatured bones.
- 15 26. The bone generating product of claim 15, in which the bone particles have an average particle size comprised between 0.5 mm and 5mm.
- 20 27. The bone generating product of claim 15, in which the calcium containing compound is selected from the group consisting of bone particles, mixture of bone particles with calcium containing additives, the product comprising from 15% to 50% by volume of bone particles.
- 25 28. The bone generating product of claim 15, in which the coagulated matrix is a coagulated matrix of platelet rich plasma having a platelet concentration of 1,500,000 to 2,000,000 platelets per microlitre of the matrix forming agents.
- 30 29. The bone generating product of claim 15, in which the coagulated matrix is a coagulated matrix of platelet rich plasma having a platelet concentration of 1,500,000 to 2,000,000 platelets per microlitre of the matrix forming agents and 0.05 to 0.4 µg thromboplastine in dry form per microlitre of the matrix forming agents.

30. The bone generating product of claim 15 for a patient, in which the platelet rich plasma is prepared from the plasma of the patient and in which the bone particles are prepared from a bone of the patient.

5 31. The bone generating product of claim 15, in which the coagulated matrix is associated with a bio compatible film.

32. The bone generating product of claim 15, which further contains at least an additive selected among the group consisting of growth factors, genes encoding 10 growth factors, calcium containing compounds, drugs, fatty acids, antibiotics, bactericides, virucides, fibrinogene, compounds inducing the formation of matrixes, and mixtures thereof

15 33. The bone generating product of claim 32, which contains as antibiotic at least an antibiotic having an anti osteoclasts effect.

34. A method for the preparation of a bone generating product comprising a coagulated matrix of platelet rich plasma with a recombinant compound for generating thrombin, and bone particles dispersed in the said matrix, in which 20

- a substantially homogeneous mixture is prepared by mixing platelet rich plasma with an amount of calcium containing compound effective for inducing the generation of bone when adding a recombinant thrombin generating compound and a phospholipid,
- a recombinant thrombin generating compound and a phospholipid are added and mixed to the mixture prepared from platelet rich plasma, and
- the mixture recombinant thrombin generating compound, phospholipid, platelet rich plasma and calcium containing compound is kept under conditions for ensuring a coagulation of the platelet rich plasma and the formation of a matrix.

25 35. The method of claim 34, in which the calcium containing compound is selected from the group consisting of bone particles, mixture of bone particles with calcium containing additives.

36. The method of claim 34, in which the coagulation is carried out in presence of oxygen and substantially without stirring.

5 37. The method of claim 34, in which the recombinant compound for generating thrombin used for the coagulation is a recombinant thromboplastine.

10 38. The method of claim 34, in which the calcium containing compound is selected from the group consisting of bone particles, mixture of bone particles with calcium containing additives, and in which at least one phospholipid is added to the mixture selected from the group consisting of mixture of recombinant thrombin generating compound, platelet rich plasma and bone particles, and mixture of platelet rich plasma and bone particles.

15 39. The method of claim 34, in which the recombinant compound for generating thrombin is combined with phospholipids.

20 40. The method of claim 34, in which the recombinant compound for generating thrombin is combined with at least a phospholipid selected from the group consisting of phosphatidylserine, derivatives thereof, phosphatidylserine having at least one fatty acid side chain, phosphatidylcholine, derivatives thereof, phosphatidylcholine having at least one fatty acid side chain, and mixtures thereof.

25 41. The method of claim 34, in which the recombinant compound for generating thrombin is combined with at least a phospholipid selected from the group consisting of phosphatidylserine, derivatives thereof, phosphatidylserine having at least one fatty acid side chain, phosphatidylcholine, derivatives thereof, phosphatidylcholine having at least one fatty acid side chain, and mixtures thereof, the fatty acid side chain being selected from the group consisting of fatty acid chains with at least one double bond and with 6 to 24 carbon atoms.

42. The method of claim 34, in which the recombinant compound for generating thrombin is combined with at least a phospholipid selected from the group consisting of phosphatidylserine, derivatives thereof, phosphatidylserine having at least one fatty acid side chain, phosphatidylcholine, derivatives thereof,  
5 phosphatidylcholine having at least one fatty acid side chain, and mixtures thereof, the fatty acid side chain being selected from the group consisting of fatty acid chains with at least one double bond and with 16 to 18 carbon atoms.

43. The method of claim 34, in which the recombinant compound for generating  
10 thrombin is combined with a mixture of at least two phospholipids, a first phospholipid being selected from the group consisting of phosphatidylserine, derivatives thereof, phosphatidylserine having at least one fatty acid side chain, and mixtures thereof, the fatty acid side chain of the phosphatidylserine having at least one fatty acid side chain being selected from the group consisting of fatty acid  
15 chains with at least one double bond and with 6 to 24 carbon atoms while the second phospholipid is selected from the group consisting of phosphatidylcholine, derivatives thereof, phosphatidylcholine having at least one fatty acid side chain, and mixtures thereof, the fatty acid side chain of the phosphatidylcholine having at least one fatty acid side chain being selected from the group consisting of fatty acid  
20 chains with at least one double bond and with 6 to 24 carbon atoms.

44. The method of claim 34, in which the calcium containing compound is selected from the group consisting of bone particles, mixture of bone particles with calcium containing additives, and in which the bone particles are bone particles selected from  
25 the group consisting of craniofacial bone particles, iliac bone particles and mixture thereof.

45. The method of claim 34, in which the calcium containing compound is selected from the group consisting of bone particles, mixture of bone particles with calcium containing additives, and in which the bone particles are particles of not denatured bones.  
30

46. The method of claim 34, in which the calcium containing compound is selected from the group consisting of bone particles, mixture of bone particles with calcium containing additives, and in which the bone particles have an average particle size comprised between 0.5 mm and 5mm.

5

47. The method of claim 34, in which the calcium containing compound is selected from the group consisting of bone particles, mixture of bone particles with calcium containing additives, and in which the amount of bone particles added to the platelet rich plasma corresponds to about 15% to 50% by volume of the mixture platelet rich plasma and bone particles.

10

48. The method of claim 34, in which the platelet rich plasma has a platelet concentration of 1,500,000 to 2,000,000 platelets per microlitre of the matrix forming agents.

15

49. The method of claim 34, in which the mixture platelet rich plasma, bone particles and recombinant thrombin generating compound has a platelet concentration of 1,500,000 to 2,000,000 platelets per microlitre of the mixture without bone particles and contains 0.05 to 0.4 µg thromboplastine in dry form per microlitre of the mixture without bone particles.

20

50. The method of claim 34, for the preparation of a bone generating product for a patient, in which the platelet rich plasma is prepared from a plasma selected from the group consisting of the plasma of the patient, a plasma hystocompatible with the patient and mixtures thereof, and in which the calcium containing compound consists essentially of bone particles prepared from at least a bone selected from the group consisting of bones of the patient, bones hystocompatible with the patient and mixtures thereof.

25

30 51. Use of a recombinant compound for generating thrombin in mixture with at least one phospholipid for the preparation of a bone generating product from a mixture of

a platelet rich plasma and an effective amount of calcium containing compound for inducing bone generation.

52. Mixture containing a recombinant compound for generating thrombin, at least  
5 one phospholipid, and a calcium containing compound, the weight ratio calcium  
from the calcium containing compound / recombinant compound for generating  
thrombin being greater than 0.5.

10 53. The mixture of claim 52, in which the weight ratio calcium from the calcium  
containing compound / recombinant compound for generating thrombin is greater  
than 2.

54. The mixture of claim 52, said mixture having the form of a dry powder.

15 55. The mixture of claim 52, in which the calcium containing compound is selected  
from the group consisting of calcium containing salts, particles of denatured bone  
and mixtures thereof.

20 56. Mixture containing a recombinant compound for generating thrombin, at least  
one phospholipid, and at least one antibiotic, the weight ratio antibiotic /  
recombinant compound for generating thrombin being greater than 1.

25 57. The mixture of claim 56, in which the antibiotic is an antibiotic having an anti  
osteoclasts effect.

58. The mixture of claim 56, in which the weight ratio antibiotic / recombinant  
compound for generating thrombin is greater than 5.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/BE 00/00152

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61L24/10 A61L26/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61L A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category | Citation of document, with indication, where appropriate, of the relevant passages                                   | Relevant to claim No.                  |
|----------|--|--|
| X        | WO 97 29792 A (COHESION CORP; SIERRA DAVID H (US)) 21 August 1997 (1997-08-21)<br>column 7, line 10 - line 24<br>--- | 1-58                                   |
| X        | US 4 427 650 A (STROETMANN MICHAEL)<br>24 January 1984 (1984-01-24)<br>example 5<br>claims 1,9<br>---                | 1,8,<br>11-14,56                       |
| A        | US 5 266 624 A (PROSISE WILLIAM E ET AL)<br>30 November 1993 (1993-11-30)<br><br>claims 1,2,5,10<br>---              | 1,11,15,<br>34,51,<br>52,56<br><br>-/- |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*a\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

18 May 2001

29/05/2001

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax (+31-70) 340-3016

Authorized officer

Heck, G

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/BE 00/00152

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages                                    | Relevant to claim No.       |
|----------|---|-----------------------------|
| A        | US 5 883 078 A (TURECEK PETER ET AL)<br>16 March 1999 (1999-03-16)<br><br>column 5, line 11 - line 42<br>claims 1,2,8 | 1,11,15,<br>34,51,<br>52,56 |
| A        | WO 99 45938 A (SIERRA DAVID H; BIOSURGICAL<br>CORP (US)) 16 September 1999 (1999-09-16)<br><br>claims 1,3-5,12,13     | 1,11,15,<br>34,51,<br>52,56 |
| A        | US 5 733 545 A (HOOD III ANDREW G)<br>31 March 1998 (1998-03-31)<br>cited in the application<br>example 4             | 15,34,<br>51,52,56          |

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

|          |                |
|----------|----------------|
| Internat | Application No |
| PCT/BE   | 00/00152       |

| Patent document cited in search report | Publication date | Patent family member(s)  |   | Publication date   |
|--|------------------|--|---|--|
| WO 9729792                             | A 21-08-1997     | CA<br>EP   | 2247133 A<br>0885020 A  | 21-08-1997<br>23-12-1998   |
| US 4427650                             | A 24-01-1984     | AT<br>AT<br>DE<br>DE<br>EP<br>EP<br>EP<br>EP<br>JP<br>JP<br>JP<br>JP<br>JP<br>JP<br>JP<br>JP<br>JP<br>US<br>US | 20824 T<br>13810 T<br>3171072 D<br>3175003 D<br>0068047 A<br>0068048 A<br>0068149 A<br>1018054 B<br>58038216 A<br>1018055 B<br>58038217 A<br>58036545 A<br>61039824 B<br>61178927 A<br>4427651 A<br>4442655 A | 15-08-1986<br>15-07-1985<br>25-07-1985<br>28-08-1986<br>05-01-1983<br>05-01-1983<br>05-01-1983<br>05-01-1983<br>03-04-1989<br>05-03-1983<br>03-04-1989<br>05-03-1983<br>03-03-1983<br>05-09-1986<br>11-08-1986<br>24-01-1984<br>17-04-1984 |
| US 5266624                             | A 30-11-1993     | NONE   |   |  |
| US 5883078                             | A 16-03-1999     | DE<br>CA<br>EP<br>JP   | 19521324 C<br>2178789 A<br>0748633 A<br>9002971 A   | 31-10-1996<br>13-12-1996<br>18-12-1996<br>07-01-1997   |
| WO 9945938                             | A 16-09-1999     | AU<br>EP   | 2900599 A<br>1061931 A  | 27-09-1999<br>27-12-2000   |
| US 5733545                             | A 31-03-1998     | AU<br>AU<br>CA<br>EP<br>JP<br>WO   | 710720 B<br>5416696 A<br>2214274 A<br>0813427 A<br>11502435 T<br>9627397 A  | 30-09-1999<br>23-09-1996<br>12-09-1996<br>29-12-1997<br>02-03-1999<br>12-09-1996   |